| 1.535 -0.065 (-4.06%) | 09-15 15:57 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.12 | 1-year : | 2.54 |
| Resists | First : | 1.82 | Second : | 2.18 |
| Pivot price | 1.78  |
|||
| Supports | First : | 1.24 | Second : | 1.03 |
| MAs | MA(5) : | 1.63 |
MA(20) : | 1.81 |
| MA(100) : | 6.62 |
MA(250) : | 6.8 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 41.6 |
D(3) : | 29.3 |
| RSI | RSI(14): 26.7 |
|||
| 52-week | High : | 10.98 | Low : | 1.24 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ KPTI ] has closed above bottom band by 22.3%. Bollinger Bands are 80.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.63 - 1.65 | 1.65 - 1.66 |
| Low: | 1.52 - 1.54 | 1.54 - 1.55 |
| Close: | 1.58 - 1.61 | 1.61 - 1.63 |
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
Fri, 11 Sep 2026
KPTI Slides As Legal, Cash Pressures Rattle Traders - StocksToTrade
Fri, 11 Sep 2026
Karyopharm Wins Forbearance to Oct. 15, Will Issue $20M 0% Convertible Preferred - TradingView
Tue, 01 Sep 2026
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Karyopharm
Fri, 14 Aug 2026
Karyopharm Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Thu, 13 Aug 2026
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 23 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 4.6 (%) |
| Held by Institutions | 93.6 (%) |
| Shares Short | 9,640 (K) |
| Shares Short P.Month | 6,310 (K) |
| EPS | -14.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -14.57 |
| Profit Margin | -153.3 % |
| Operating Margin | -67.4 % |
| Return on Assets (ttm) | -47.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -11.9 % |
| Gross Profit (p.s.) | 0.86 |
| Sales Per Share | 6.46 |
| EBITDA (p.s.) | -3.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -65 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -0.12 |
| PEG Ratio | 0 |
| Price to Book value | -0.12 |
| Price to Sales | 0.25 |
| Price to Cash Flow | -0.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|